Merck Investor update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. Good evening, everyone. Welcome to the investor event of Merck & Co., Inc., Rahway, New Jersey, U.S.A., at the European Society for Medical Oncology Annual Meeting. Thank you to all of you who have made the effort to be with us here in Madrid, and thank you to everyone tuning in via the webcast. We are obviously very excited to have this opportunity to speak to you about the data that was presented this weekend in our oncology program. During today's call, a slide presentation will accompany our speakers' prepared remarks and has been posted to the investor relations section of our website. Before we get started, we would like to remind you that some of the statements that we make during today's call may be considered forward-looking statements within the meaning of the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995.
Such statements are made based on the current beliefs of our company's management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Please reference this slide in our presentation and our 2025 10-K, which identifies certain risk factors and cautionary statements. Again, thank you for coming tonight. Dr. Eliav Barr, Senior Vice President, Head of Global Clinical Development, and Chief Medical Officer, will begin our program with opening remarks. Then Dr. Marjorie Green, Senior Vice President and Head of Oncology Global Clinical Development, will provide an overview of the key data updates we presented at ESMO. Eliav will then return with a few closing remarks before we get to all of your Q&A. With that, I am happy to turn it over to Eliav.
Great. Sorry, it is a bit rickety up here. All right. Thank you, Peter, and thanks to all of you for joining us. It is a real pleasure to be here at ESMO and to have a discussion on the ongoing progress of our oncology portfolio. This has been a really amazing, tremendous ESMO for our company. We have had three presidential symposium presentations that I think in many ways reflect the way in which we have been working to accomplish across the oncology portfolio. Before Marjorie reviews the individual datasets, I would like to take a step back and put them in context of that broader strategy. As many of you know, in 2021, we outlined two strategic objectives to sustain durable leadership in oncology.
First, we sought to maximize the impact of KEYTRUDA and continue to move into earlier stages of disease where we believe we have the greatest impact on long-term patient outcomes. We also committed to diversifying our oncology pipeline with innovative investigational candidates with novel mechanisms, and these objectives continue to guide our oncology strategy today. Over the last several years, we have expanded KEYTRUDA's impact across tumor types and treatment settings, including through the introduction of KEYTRUDA QLEX, which may offer patients and providers a more convenient administration option compared to KEYTRUDA, while providing a comparable efficacy and safety profile to KEYTRUDA. At the same time, I think we have built a broad pipeline of innovative assets designed to address important biological drivers of cancer and potentially improve outcomes for patients across a wide range of malignancies.
Today, we believe that we are uniquely positioned to advance cancer care through a differentiated portfolio spanning three complementary pillars of biology. The first is immuno-oncology, where we continue to build on our leadership with KEYTRUDA while advancing next-generation approaches such as intismeran autogene and MK-2010. The second is precision molecular targeting, where we are pursuing therapies directed at key oncogenic drivers and disease pathways. The third is tissue targeting, including antibody drug conjugates, T-cell engagers designed to deliver potent therapies precisely to tumor cells. Importantly, these are not isolated programs. Our strategy is to develop medicines that can stand on their own but also work together through rational combinations informed by biology and clinical experience, and an increasingly sophisticated understanding of the disease. This approach allows us to build treatment paradigms that potentially improve efficacy while expanding the number of patients who might benefit from these medicines.
Now, the breadth of our portfolio and the diversity of mechanisms represented within it provide us with a strong foundation for long-term innovation. Underlying all of our developmental efforts are several core principles. First, we believe that the best outcomes are often achieved when therapies with different and complementary mechanisms are combined or used sequentially. Second, we are committed to improving therapeutic precision through biomarker-driven approaches that help identify patients who can benefit the most. Then third, we continue to prioritize earlier-stage and potentially curative settings where the opportunity to change the course of disease may be the greatest. These principles have shaped our development philosophy across the portfolio, and they are reflected in the programs you will hear today. Importantly, the data being presented at ESMO provide additional validation to this approach and demonstrate meaningful progress across several of our most important oncology programs.
Without further ado, I know you want to hear about the datasets. I will turn it over to Marjorie.
Thank you, Elliot. Hello, all y'all. I hope you have been surviving ESMO and the fun of the marathon at sprint speed. As I look across our oncology portfolio today, what strikes me is how much it has evolved over the last decade. Many of our most important scientific presentations historically centered on KEYTRUDA, and rightfully so. Throughout the KEYTRUDA program, we fundamentally changed the treatment landscape for many cancers and developed a deeper understanding of how immunotherapy can benefit patients across different tumor types. Today, KEYTRUDA continues to be an important part of our strategy. We remain focused on extending benefit into earlier stages of disease, understanding long-term outcomes, and identifying those patients most likely to benefit from treatment. What you are seeing at ESMO this year is also the next chapter of our oncology story.
The experience we gained through the development of KEYTRUDA has shaped how we think about biomarkers, combination approaches, earlier intervention, and precision medicine. It is directly informed our investments in areas such as individualized neoantigen therapy and antibody-drug conjugates. In many ways, the data we presented demonstrates how we are applying the lessons of the first generation of immuno-oncology to the next generation of cancer medications and combinations. Data was highlighted by three presidential symposia. INTerpath-001 demonstrates the promise of individualized neoantigen therapy, continued evolution of the treatment approaches enhancing immune targeting of cancer, and represents the first Phase III data for INT plus KEYTRUDA in the adjuvant setting for certain patients with melanoma. TroFuse-005 demonstrates the potential of sac-TMT in certain patients with advanced or recurrent endometrial cancer and marks the first global Phase III study from our broad program of 18 global Phase III trials.
Finally, the third presentation was KEYNOTE-C93, advancing our understanding of how to optimally use KEYTRUDA in certain types of endometrial cancer. Together, these studies reflect both the promise of our existing portfolio and the emergence of new platforms built upon lessons learned through KEYTRUDA development that have the potential to benefit patients across a broad range of cancers. Let me start with sac-TMT, which is one of the broadest development programs currently underway in our oncology portfolio. You have heard us describe that each ADC is unique. Not all ADCs are the same. ADCs are generally designed to deliver highly potent cytotoxic therapy preferentially to cancer cells versus normal tissue. Differences in molecular design of an ADC can have important implications for clinical performance. What particularly excites us about sac-TMT is the thoughtful design of this molecule.
Sac-TMT is a Trop-2-directed ADC with a belotecan-derived topoisomerase 1 inhibitor payload and a unique bifunctional linker that we brought in through our partnership with Kelun-Biotech. The linker includes an irreversible connection to the antibody intended to minimize payload loss in the circulation, along with a pH-sensitive release mechanism designed to facilitate intracellular and intratumoral delivery within tumor cells and supporting bystander effect. This design is also supported by a drug-to-antibody ratio of approximately 7.4. It is not just the potency of the payload that is important, it is the totality of the structure of the antibody-drug conjugate that you need to pay attention to, and we think this one is very special.
Based upon the clinical experience generated to date, the encouraging data presented by Kelun and the first global Phase III from our TroFuse program, we believe sac-TMT has the potential to become a cornerstone ADC across multiple tumor types. Today, we will talk about the first global Phase III data from the TroFuse development program. It is important to understand the clinical context of endometrial cancer, which remains an area of significant unmet need. It is the sixth most common cancer in women globally, and unlike many cancers, it is one of the cancers that is rising in incidence, and mortality continues to rise. According to the American Cancer Society, there are an estimated 68,000 new cases of endometrial cancer per year, and more than 14,000 deaths from endometrial cancer in the United States are anticipated in 2026.
Endometrial cancer is not only a growing significant health challenge, it is also associated with significant healthcare disparities. Mortality rates among Black women remain approximately double of those amongst white women. Before the introduction of immunotherapy and KEYTRUDA had its first accelerated approval in 2019, patients' outcomes who had endometrial cancer that were recurrent were quite poor, with survival ranging between 12-24 months. Since then, we have learned a great deal about the importance of understanding the biology of endometrial cancer, biomarkers such as mismatch repair status, and KEYTRUDA-based regimens, and these have fundamentally changed outcome for many people with endometrial cancer. The challenge is that once the endometrial cancer has progressed after chemotherapy and an anti-PD-1 or PD-L1 immunotherapy, treatment options become very limited and survival is typically measured in months rather than in years. That was the unmet need that TroFuse-005 was designed to address.
TroFuse-005 is our first global phase III study with sac-TMT that has been presented, demonstrated a statistically significant and clinically meaningful improvement in all three clinical endpoints of progression-free survival, overall survival, and overall response rate when compared with treatment of physician's choice, which is single-agent chemotherapy. This occurred in certain patients with recurrent or advanced endometrial cancer. It reduced the risk of disease progression or death by 41% and reduced the risk of death and improved overall survival and reduced that risk by 32%. The progression increase from 3.9 to 7.2 months is important for these people. What I was very encouraged by was that absolute improvement of a near seven-month improvement in overall survival for people whose lifespans had been measured in usually less than a year and in months.
We are getting up to 19 months in this end stage setting for many people diagnosed with endometrial cancer. The overall response rates doubled, going from 17.3% or almost doubled to 35%. Another thing that I would like to highlight is the duration of response of 11.1 months. It is that duration of response combined with that overall response rates that really translates to that clinically compelling efficacy that was seen. Equally important, the responses were very deep and the durability I just talked about. I think that this data represents a meaningful advance for these people with advanced endometrial cancer who have received a platinum-based therapy and a PD or PD-L1-based treatment. Treatment options are quite limited for them, so this is exciting information for us to see and potentially gives hope to people with this disease.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
13 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
